ArticleBMC infectious diseases2026
Association of age-stratified cytokine profiles with clinical outcomes in patients with severe fever with thrombocytopenia syndrome.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere fever with thrombocytopenia syndrome (SFTS) is a life-threatening zoonotic disease characterized by high morbidity and mortality. The aim of this study was to investigate the associations between serum cytokine levels and clinical outcomes in SFTS patients across different age groups to obtain deeper insights into disease pathogenesis.
methodsA total of 807 SFTS patients were enrolled in this two-center cohort study from January 2021 to December 2023. Serum samples from 78 of these patients were analyzed to determine the levels of 48 cytokines via the Luminex 200 platform. Patients were stratified by age and clinical outcome, and cytokine levels were compared across groups.
resultsThis study included 807 SFTS patients with an average age of 63.65 ± 10.63 years. Receiver operating characteristic (ROC) curve analysis was performed in the training cohort to evaluate the ability of age to predict clinical outcomes, and 66.5 years was identified as the optimal cutoff value (AUC 0.780, 95% CI 0.741-0.818). Based on this cutoff value and clinical outcomes, the 78 patients were stratified into four groups: older survivors, older non-survivors, younger survivors, and younger non-survivors. In this limited cohort, no significant differences in cytokine levels were observed between older and younger non-survivors, nor between older and younger survivors (FDR-adjusted q > 0.05). However, multiple cytokines were significantly elevated in non-survivors compared with survivors across age strata (q < 0.05), including representative cytokines such as IL-1β, IL-6, IL-10, IFN-γ, MCP-1, and MCP-3.
conclusionCytokine levels were associated with clinical outcomes in patients with SFTS. These findings suggest that cytokine profiles may serve as potential biomarkers reflecting disease severity. Early identification of high-risk patients and the exploration of cytokine-targeted therapies warrant further investigation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.